Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
11/09/2020 11:30 AM EST The trial began after lab studies and preliminary reports suggested that hydroxychloroquine might have promise in treating SARS-CoV-2. |
Monday, November 9, 2020
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
Subscribe to:
Post Comments (Atom)
J.P. Morgan preparing for market meltdown?
Why is J.P. Morgan stockpiling silver? ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ...
-
insidecroydon posted: " Become a Patron! What's on inside Croydon: Click here for the latest events listing...
No comments:
Post a Comment